Fluvastatin inhibits expression of the chemokine MDC/CCL22 induced by interferon-g in HaCaT cells, a human keratinocyte cell line

British Journal of Pharmacology

Volumn 157, Issue 8, 2009, Pages 1441-1450

  Qi, Xu Feng ^a   Kim, Dong Heui ^a   Yoon, Yang Suk ^a   Li, Jian Hong ^b   Jin, Dan ^c   Teng, Yung Chien ^a   Kim, Soo Ki ^a   Lee, Kyu Jae ^a  

^a Yonsei University Wonju College of Medicine   (South Korea)

^b HUAZHONG AGRICULTURAL UNIVERSITY   (China)

^c YANBIAN UNIVERSITY   (China)

Author keywords

Atopic dermatitis (AD); Fluvastatin; HaCaT cells; MDC CCL22

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACROPHAGE DERIVED CHEMOKINE; MITOGEN ACTIVATED PROTEIN KINASE P38; SIMVASTATIN;

ARTICLE; ATOPIC DERMATITIS; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELL LINE; CHEMOKINE CCL22; FATTY ACIDS, MONOUNSATURATED; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; INTERFERON-GAMMA; KERATINOCYTES; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRROLES; SIGNAL TRANSDUCTION; SIMVASTATIN; TH2 CELLS;

EID: 70350323989     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00311.x     Document Type: Article

References (56)

1. Alaei P, MacNulty EE, Ryder NS (1996). Inhibition of protein preny-lation down-regulates signalling by inflammatory mediators in human keratinocytes. Biochem Biophys Res Commun 222: 133-138.
2. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE (1988). Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106: 761-771.
3. Bustos C, Hernandez-Presa MA, Ortego M, Tunon J, Ortega L, Perez F et al. (1998). HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 32: 2057-2064.
4. Carlin CM, Peacock AJ, Welsh DJ (2007). Fluvastatin inhibits hypoxic proliferation and p38 MAPK activity in pulmonary artery fibro-blasts. Am J Respir Cell Mol Biol 37: 447-456.
5. Efthymiou CA, Mocanu MM, Yellon DM (2005). Atorvastatin and myocardial reperfusion injury: new pleiotropic effect implicating multiple prosurvival signaling. J Cardiovasc Pharmacol 45: 247-252.
6. Ferro D, Parrotto S, Basili S, Alessandri C, Violi F (2000). Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 36: 427-431.
7. Fujii-Maeda S, Kajiwara K, Ikizawa K, Shinazawa M, Yu B, Koga T et al. (2004). Reciprocal regulation of thymus and activation-regulated chemokine/macrophage-derived chemokine production by inter-leukin (IL)-4/IL-13 and interferon-gamma in HaCaT keratinocytes is mediated by alternations in E-cadherin distribution. J Invest Derma-tol 122: 20-28.
8. Furukawa H, Nakamura K, Zheng X, Tojo M, Oyama N, Akiba H et al. (2004). Enhanced TARC production by dust-mite allergens and its modulation by immunosuppressive drugs in PBMCs from patients with atopic dermatitis. J Dermatol Sci 35: 35-42.
9. Goh KC, Haque SJ, Williams BR (1999). p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J 18: 5601-5608.
10. Grip O, Janciauskiene S, Lindgren S (2002). Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes. Inflamm Res 51: 58-62.
11. Haloui M, Meilhac O, Jandrot-Perrus M, Michel JB (2003). Atorvastatin limits the pro-inflammatory response of rat aortic smooth muscle cells to thrombin. Eur J Pharmacol 474: 175-184.
12. Hashimoto S, Nakamura K, Oyama N, Kaneko F, Tsunemi Y, Saeki H et al. (2006). Macrophage-derived chemokine (MDC)/CCL22 produced by monocyte derived dendritic cells reflects the disease activity in patients with atopic dermatitis. J Dermatol Sci 44: 93-99.
13. Hillyard DZ, Cameron AJ, McIntyre AH, Hadden MH, Marshall HE, Johnston N et al. (2002). Inhibition of proliferation and signalling mechanisms in human lymphocytes by fluvastatin. Clin Exp Pharmacol Physiol 29: 673-678.
14. Horikawa T, Nakayama T, Hikita I, Yamada H, Fujisawa R, Bito T et al. (2002). IFN-gamma-inducible expression of thymus and activation-regulated chemokine/CCL17 and macrophage-derived chemokine/CCL22 in epidermal keratinocytes and their roles in atopic dermatitis. Int Immunol 14: 767-773.
15. Hothersall E, McSharry C, Thomson NC (2006). Potential therapeutic role for statins in respiratory disease. Thorax 61: 729-734.
16. Ikeda U, Shimada K (1999). Statins and monocytes. Lancet 353: 2070.
17. Imai T, Chantry D, Raport CJ, Wood CL, Nishimura M, Godiska R et al. (1998). Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4. J Biol Chem 273: 1764-1768. (Pubitemid 28133708)
18. Ito T, Ikeda U, Yamamoto K, Shimada K (2002). Regulation of interleukin-8 expression by HMG-CoA reductase inhibitors in human vascular smooth muscle cells. Atherosclerosis 165: 51-55. (Pubitemid 35223167)
19. Kakinuma T, Nakamura K, Wakugawa M, Mitsui H, Tada Y, Saeki H et al. (2001). Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol 107: 535-541.
20. Kakinuma T, Nakamura K, Wakugawa M, Mitsui H, Tada Y, Saeki H et al. (2002). Serum macrophage-derived chemokine (MDC) levels are closely related with the disease activity of atopic dermatitis. Clin Exp Immunol 127: 270-273.
21. Kanda N, Watanabe S (2007). Prolactin enhances interferon-gamma-induced production of CXC ligand 9 (CXCL9), CXCL10, and CXCL11 in human keratinocytes. Endocrinology 148: 2317-2325. (Pubitemid 46997044)
22. Kanda N, Shimizu T, Tada Y, Watanabe S (2007). IL-18 enhances IFN-gamma-induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes. Eur J Immunol 37: 338-350.
23. Kim DY, Ryu SY, Lim JE, Lee YS, Ro JY (2007). Anti-inflammatory mechanism of simvastatin in mouse allergic asthma model. Eur J Pharmacol 557: 76-86.
24. Kwak B, Mulhaupt F, Myit S, Mach F (2000). Statins as a newly recognized type of immunomodulator. Nat Med 6: 1399-1402.
25. Lehmann B (1997). HaCaT cell line as a model system for vitamin D3 metabolism in human skin. J Invest Dermatol 108: 78-82.
26. Mach F (2002). Statins as immunomodulators. Transpl Immunol 9: 197-200.
27. McKay A, Leung BP, McInnes IB, Thomson NC, Liew FY (2004). A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol 172: 2903-2908.
28. Morel JC, Park CC, Zhu K, Kumar P, Ruth JH, Koch AE (2002). Signal transduction pathways involved in rheumatoid arthritis synovial fibroblast interleukin-18-induced vascular cell adhesion molecule-1 expression. J Biol Chem 277: 34679-34691.
29. Mowen KA, Tang J, Zhu W, Schurter BT, Shuai K, Herschman HR et al. (2001). Arginine methylation of STAT1 modulates IFNalpha/beta-induced transcription. Cell 104: 731-741.
30. Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A (2001). Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol 77: 247-253.
31. Nakajima K, Suga H, Matsuno H, Ishisaki A, Hirade K, Kozawa O (2006). Differential roles of MAP kinases in atorvastatin-induced VEGF release in cardiac myocytes. Life Sci 79: 1214-1220.
32. Nakayama T, Hieshima K, Nagakubo D, Sato E, Nakayama M, Kawa K et al. (2004). Selective induction of Th2-attracting chemokines CCL17 and CCL22 in human B cells by latent membrane protein 1 of Epstein-Barr virus. J Virol 78: 1665-1674.
33. Neuhaus O, Strasser-Fuchs S, Fazekas F, Kieseier BC, Niederwieser G, Hartung HP et al. (2002). Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 59: 990-997.
34. Nguyen VA, Chen J, Hong F, Ishac EJ, Gao B (2000). Interferons activate the p42/44 mitogen-activated protein kinase and JAK-STAT (Janus kinase-signal transducer and activator transcription factor) signalling pathways in hepatocytes: differential regulation by acute ethanol via a protein kinase C-dependent mechanism. Biochem J 349: 427-434.
35. Ogunwobi OO, Beales IL (2008). Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol 103: 825-837.
36. Ortego M, Gomez-Hernandez A, Vidal C, Sanchez-Galan E, Blanco-Colio LM, Martin-Ventura JL et al. (2005). HMG-CoA reductase inhibitors reduce I kappa B kinase activity induced by oxidative stress in monocytes and vascular smooth muscle cells. J Cardiovasc Pharmacol 45: 468-475.
37. Osorio JC, Cheema FH, Martens TP, Mahmut N, Kinnear C, Gonzalez AM et al. (2008). Simvastatin reverses cardiac hypertrophy caused by disruption of the bradykinin 2 receptor. Can J Physiol Pharmacol 86: 633-642.
38. Ou XM, Wang BD, Wen FQ, Feng YL, Huang XY, Xiao J (2008). Simvastatin attenuates lipopolysaccharide-induced airway mucus hypersecretion in rats. Chin Med J (Engl) 121: 1680-1687.
39. Rose DM, Winston BW, Chan ED, Riches DW, Henson PM (1997). Interferon-gamma and transforming growth factor-beta modulate the activation of mitogen-activated protein kinases and tumor necrosis factor-alpha production induced by Fc gamma-receptor stimulation in murine macrophages. Biochem Biophys Res Commun 238: 256-260.
40. Rosenson RS, Tangney CC, Casey LC (1999). Inhibition of proinflam-matory cytokine production by pravastatin. Lancet 353: 983-984.
41. Rothe G, Herr AS, Stohr J, Abletshauser C, Weidinger G, Schmitz G (1999).Amorematurephenotypeofblood mononuclearphagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart disease. Atherosclerosis 144: 251-261.
42. Sakoda K, Yamamoto M, Negishi Y, Liao JK, Node K, Izumi Y (2006). Simvastatin decreases IL-6 and IL-8 production in epithelial cells. J Dent Res 85: 520-523.
43. Samson KT, Minoguchi K, Tanaka A, Oda N, Yokoe T, Yamamoto Y et al. (2006). Inhibitory effects of fluvastatin on cytokine and chemokine production by peripheral blood mononuclear cells in patients with allergic asthma. Clin Exp Allergy 36: 475-482.
44. Shen H, Lentsch AB (2004). Progressive dysregulation of transcription factors NF-kappa B and STAT1 in prostate cancer cells causes proan-giogenic production of CXC chemokines. Am J Physiol Cell Physiol 286: C840-C847.
45. Shimada Y, Takehara K, Sato S (2004). Both Th2 and Th1 chemokines (TARC/CCL17, MDC/CCL22, and Mig/CXCL9) are elevated in sera from patients with atopic dermatitis. J Dermatol Sci 34: 201-208.
46. Sundararaj KP, Samuvel DJ, Li Y, Nareika A, Slate EH, Sanders JJ et al. (2008). Simvastatin suppresses LPS-induced MMP-1 expression in U937 mononuclear cells by inhibiting protein isoprenylation-mediated ERK activation. J Leukoc Biol 84: 1120-1129.
47. Takahashi HK, Mori S, Iwagaki H, Yoshino T, Tanaka N, Weitz-Schmidt G et al. (2005). Differential effect of LFA703, pravastatin, and fluv-astatin on production of IL-18 and expression of ICAM-1 and CD40 in human monocytes. J Leukoc Biol 77: 400-407. (Pubitemid 40289570)
48. Turner NA, Midgley L, O'Regan DJ, Porter KE (2007). Comparison of the efficacies of five different statins on inhibition of human saphe-nous vein smooth muscle cell proliferation and invasion. J Cardio-vasc Pharmacol 50: 458-461.
49. Van Linthout S, Riad A, Dhayat N, Spillmann F, Du J, Dhayat S et al. (2007). Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy. Diabe-tologia 50: 1977-1986.
50. Wagner AH, Schwabe O, Hecker M (2002). Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ. Br J Pharmacol 136: 143-149.
51. Wang HR, Li JJ, Huang CX, Jiang H (2005). Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reactive protein. Clin Chim Acta 353: 53-60.
52. Yang BC, Wang YS, Liu HS, Lin SJ (2000). Ras signaling is involved in the expression of Fas-L in glioma. Lab Invest 80: 529-537.
53. Yang J, Li XP, Zhao SP, Li J, Li JD, Xie XM (2006). The effect of different doses of fluvastatin on inflammatory markers in the early phase of acute coronary syndrome. Clin Chim Acta 368: 183-187.
54. Yoshie O, Imai T, Nomiyama H (2001). Chemokines in immunity. Adv Immunol 78: 57-110.
55. Zamvil SS, Steinman L (2002). Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment of MS. Neurology 59: 970-971.
56. Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S (2002). Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 45: 147-154.